AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilokibart, showing promising Phase 2 results for skin clearance, and a combination therapy for asthma. The deal, approved by both companies' boards, is expected to close in Q3 2026 pending regulatory and shareholder approval. AbbVie expects the acquisition to strengthen its immunology portfolio and be accretive to earnings by 2032.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
